ABSTRACT
Purpose
In an effort to apply the imaging techniques currently used in disease diagnosis for monitoring the pharmacokinetics and biodisposition of particulate drug carriers, we sought to use computed tomography (CT) scanning methodology to investigate the impact of surfactant on the blood residence time of emulsions.
Methods
We prepared the iodinated oil Lipiodol emulsions with different compositions of surfactants and investigated the impact of surfactant on the blood residence time of emulsions by CT scanning.
Results
The blood circulation time of emulsions was prolonged by including Tween 80 or DSPE-PEG (polyethylene glycol 2000) in emulsions. Tween 80 was less effective than DSPE-PEG in terms of prolongation effect, but the blood circulating time of emulsions was prolonged in a Tween 80 content-dependent manner. As a proof-of-concept demonstration of the usefulness of CT-guided screening in the process of formulating drugs that need to be loaded in emulsions, paclitaxel was loaded in emulsions prepared with 87 or 65% Tween 80–containing surfactant mixtures. A pharmacokinetics study showed that paclitaxel loaded in 87% Tween 80 emulsions circulated longer in the bloodstream compared to those in 65% Tween 80 emulsions, as predicted by CT imaging.
Conclusions
CT-visible, Lipiodol emulsions enabled the simple evaluation of surfactant composition effects on the biodisposition of emulsions.
Similar content being viewed by others
REFERENCES
Mirtallo JM, Dasta JF, Kleinschmidt KC, Varon J. State of the art review: intravenous fat emulsions: current applications, safety profile, and clinical implications. Ann Pharmacother. 2010;44:688–700.
Hippalgaonkar K, Majumdar S, Kansara V. Injectable lipid emulsions-advancements, opportunities and challenges. AAPS PharmSciTech. 2010;11:1526–40.
Prankerd RJ, Stella VJ. The use of oil-in-water emulsions as a vehicle for parenteral drug administration. J Parenter Sci Technol. 1990;44:139–49.
Zhao H, Lu H, Gong T, Zhang Z. Nanoemulsion loaded with lycobetaine-oleic acid ionic complex: physicochemical characteristics, in vitro, in vivo evaluation, and antitumor activity. Int J Nanomedicine. 2013;8:1959–73.
Ragelle H, Crauste-Manciet S, Seguin J, Brossard D, Scherman D, Arnaud P, et al. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Int J Pharm. 2012;427:452–9.
Bhandari R, Kaur IP. Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm. 2013;441:202–12.
Rajpoot P, Bali V, Pathak K. Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan. Int J Pharm. 2012;426:219–30.
Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, Hisaoka M. Pharmacokinetics of highly lipophilic antitumor agent palmitoyl rhizoxin incorporated in lipid emulsions in rats. Biol Pharm Bull. 1996;19:252–8.
Talegaonkar S, Vyas SP. Inverse targeting of diclofenac sodium to reticuloendothelial system-rich organs by sphere-in-oil-in-water (s/o/w) multiple emulsion containing poloxamer 403. J Drug Target. 2005;13:173–8.
Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, Sasagawa K, et al. Lipid emulsions of palmitoylrhizoxin: effects of composition on lipolysis and biodistribution. Biopharm Drug Dispos. 1996;17:331–42.
Jia L, Shen J, Zhang D, Duan C, Liu G, Zheng D, et al. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Int J Biol Macromol. 2012;50:523–9.
Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials. 2006;27:4356–73.
Liu F, Liu D. Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm Res. 1995;12:1060–4.
Rossi J, Giasson S, Khalid MN, Delmas P, Allen C, Leroux JC. Long-circulating poly(ethylene glycol)-coated emulsions to target solid tumors. Eur J Pharm Biopharm. 2007;67:329–38.
Yoshizawa Y, Kono Y, Ogawara K, Kimura T, Higaki K. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm. 2011;412:132–41.
He H, David A, Chertok B, Cole A, Lee K, Zhang J, et al. Magnetic nanoparticles for tumor imaging and therapy: a So-called theranostic system. Pharm Res. 2013;30:2445–58.
Guthi JS, Yang SG, Huang G, Li S, Khemtong C, Kessinger CW, et al. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol Pharm. 2010;7:32–40.
Jarzyna PA, Skajaa T, Gianella A, Cormode DP, Samber DD, Dickson SD, et al. Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle platform for tumor targeting and imaging. Biomaterials. 2009;30:6947–54.
Soundararajan A, Bao A, Phillips WT, Perez R, Goins BA. [Re-186]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol. 2009;36:515–24.
Hallouard F, Briancon S, Anton N, Li X, Vandamme T, Fessi H. Iodinated nano-emulsions as contrast agents for preclinical X-ray imaging: impact of the free surfactants on the pharmacokinetics. Eur J Pharm Biopharm. 2013;83:54–62.
Kircher MF, Willmann JK. Molecular body imaging: MR imaging, CT, and US. part I. principles. Radiology. 2012;263:633–43.
Kweon S, Lee HJ, Hyung WJ, Suh J, Lim JS, Lim SJ. Liposomes coloaded with iopamidol/lipiodol as a RES-targeted contrast agent for computed tomography imaging. Pharm Res. 2010;27:1408–15.
Chung YE, Hyung WJ, Kweon S, Lim SJ, Choi J, Lee MH, et al. Feasibility of interstitial CT lymphography using optimized iodized oil emulsion in rats. Invest Radiol. 2010;45:142–8.
Kong WH, Lee WJ, Cui ZY, Bae KH, Park TG, Kim JH, et al. Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging. Biomaterials. 2007;28:5555–61.
Lu Y, Zhang Y, Yang Z, Tang X. Formulation of an intravenous emulsion loaded with a clarithromycin-phospholipid complex and its pharmacokinetics in rats. Int J Pharm. 2009;366:160–9.
Yang SH, Choi HG, Lim SJ, Lee MG, Kim SH. Effects of morin on the pharmacokinetics of etoposide in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in female Sprague–Dawley rats. Oncol Rep. 2013;29:1215–23.
Yang SH, Lee JH, Lee DY, Lee MG, Lyuk KC, Kim SH. Effects of morin on the pharmacokinetics of docetaxel in rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors. Arch Pharm Res. 2011;34:1729–34.
Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm. 1993;21:1–17.
Wang LZ, Ho PC, Lee HS, Vaddi HK, Chan YW, Yung CS. Quantitation of paclitaxel in micro-sample rat plasma by a sensitive reversed-phase HPLC assay. J Pharm Biomed Anal. 2003;31:283–9.
Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level–time curve. J Pharmacokinet Biopharm. 1978;6:539–46.
Gref R, Domb A, Quellec P, Blunk T, Muller RH, Verbavatz JM, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliver Rev. 2012;64:316–26.
Kan P, Chen ZB, Lee CJ, Chu IM. Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J Control Release. 1999;58:271–8.
Lim SJ, Kim CK. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm. 2002;243:135–46.
Hinrichs WL, Mancenido FA, Sanders NN, Braeckmans K, De Smedt SC, Demeester J, et al. The choice of a suitable oligosaccharide to prevent aggregation of PEGylated nanoparticles during freeze thawing and freeze drying. Int J Pharm. 2006;311:237–44.
Jansen T, Hofmans MP, Theelen MJ, Schijns VE. Structure-activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses. Vaccine. 2005;23:1053–60.
Lee IH, Park YT, Roh K, Chung H, Kwon IC, Jeong SY. Stable paclitaxel formulations in oily contrast medium. J Control Release. 2005;102:415–25.
Park JH, Yan YD, Chi SC, Hwang DH, Shanmugam S, Lyoo WS, et al. Preparation and evaluation of Cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process. J Pharm Pharmacol. 2011;63:491–9.
Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, et al. Influence of Cremophor EL on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res. 2002;8:1237–41.
Wang Y, Wu KC, Zhao BX, Zhao X, Wang X, Chen S, et al. A novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety. J Biomed Biotechnol. 2011;2011:854–72.
Malhi S, Dixit K, Sohi H, Shegokar R. Expedition of liposome to intracellular targets in solid tumors after intravenous administration. J Pharm Invest. 2013;43:75–87.
Gabizon A, Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta. 1992;1103:94–100.
ACKNOWLEDGMENTS AND DISCLOSURES
This study was supported by grants from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (Nos. 2010-0008838, 2012R1A2A2A01046171).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Lee, EH., Hong, SS., Kim, S.H. et al. Computed Tomography-Guided Screening of Surfactant Effect on Blood Circulation Time of Emulsions: Application to the Design of an Emulsion Formulation for Paclitaxel. Pharm Res 31, 2022–2034 (2014). https://doi.org/10.1007/s11095-014-1304-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-014-1304-8